Quantum Leaps in Neurology CereSync

Transforming Healthcare with Tech Innovation

CereSync Corp. is at the forefront of healthcare technology, pioneering a groundbreaking mission to revolutionize personalized care through the innovative integration of artificial intelligence (AI) and quantum technologies.


AI-Quantum Healthcare Company

CereSync's Innovation

CereSync, led by Dr. Philippe Douyon and Quanda Francis, is developing a groundbreaking platform integrating AI and Quantum computing to proactively address dementia care and other healthcare challenges.

Leadership Expertise

Dr. Douyon's neurology expertise and Quanda Francis's recognition in tech entrepreneurship position CereSync as a leader in AI-driven and Quantum Computing healthcare transformation.

Urgent Response to Dementia

CereSync recognizes the global challenge of rising dementia cases, emphasizing the need for accurate and accessible assessment tools to address misdiagnoses and lack of treatment for reversible causes.

About CereSync Company

Driven by a Mission

CereSync, a groundbreaking healthcare technology startup, is pioneering an innovative approach to dementia care under the leadership of Dr. Philippe Douyon, MD, and Quanda Francis.

CereSync Corp. is dedicated  to empowering individuals to take an active role in managing their health and well-being. We are also focused on enhancing diagnostic accuracy and personalized medical care. Our Motto "One Brain, One Body" guides our mission to  enhance computational efficiency, elevate diagnostic accuracy, and pioneer personalized healthcare. Our mission is rooted in the promise of transformative advancements that will shape the future of healthcare.

What We Know

According to the World Health Organization (WHO), the world's population of people 60 years and older will double by 2050. The Alzheimer's Society states that age is the biggest risk factor for developing dementia. The WHO states that there are currently 55 million people worldwide living with dementia. It's estimated that in the United States there are currently more than 6 million people living with Alzheimer’s Disease (AD) and related dementias. By 2050 this number is projected to rise to almost 13 million. In the near future we will have substantially higher numbers of people diagnosed with dementia and AD. There will be larger numbers of symptomatic people who will be misdiagnosed with AD due to the inaccuracies in current diagnostic tests. Even more concerning, there are large numbers of people who will never be diagnosed and treated for reversible causes of dementia due to lack of access to the healthcare system.


Diagnosis of dementia is both inadequate and for a lot of people inaccessible. People who visit their Primary Care Physicians with mild symptoms often do not meet the criteria to be referred for tests and so can experience long delays before they are diagnosed. Even more troubling, the Alzheimer’s Association reports that in the community setting, 50-70% of symptomatic patients are incorrectly diagnosed with AD and that number is reduced to 25%-30% misdiagnosed in specialized memory clinics. The Association faults the inconsistency of routine cognitive screening and the lack of easily accessible, and accurate assessment tools.

Untitled design (48)

Making the Diagnosis: Is it Dementia? Can we accurately specify the type of Dementia it is (e.g., Alzheimer’s Disease, Vitamin Deficiency, Thyroid Dysfunction, Depression, etc.,)?

There is widespread misunderstanding and confusion about dementia. The National Institute of Aging (NIA) defines dementia as: The loss of cognitive functioning — thinking, remembering and reasoning — to such an extent that it interferes with a person's daily life and activities.

According to the CDC, dementia can be caused by many conditions, some of which are reversible, while others are not. Irreversible causes of dementia include Lewy body, vascular and front-temporal dementia, and Alzheimer’s Disease. Some people may have a reversible cause of dementia such as Depression, Normal Pressure Hydrocephalus, Thyroid Dysfunction, Vitamin B 12 deficiency, all of which can be easily identified and treated. But treating any type of dementia is not possible without an accurate and easily accessible assessment tool.

Meet The Leadership Team

Pioneering Minds, Transforming Healthcare: Meet the Visionary Leaders Steering CereSync's Innovation in Dementia Care.

Quanda Francis

Co-Founder and Chief Scientific Officer


Philippe Douyon, MD

Co-Founder and Chief Medical Officer


Let’s Talk!

Get in touch with us using the enquiry form or contact details below.

    Quick Contact

    Email: info@Cere-Sync.com

    Follow us

    Copyright © 2023-2024 CereSync Corp. All Rights Reserved. Unauthorized use or reproduction of content is prohibited.